D-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence.

D-chiro-inositol male infertility sperm mitochondrial membrane potential

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
07 May 2020
Historique:
received: 24 04 2020
revised: 05 05 2020
accepted: 06 05 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 13 5 2020
Statut: epublish

Résumé

The use of inositols in endocrinological clinical practice is increasingly widespread. Most of the existing evidence concerns myoinositol (MYO), the most abundant form in nature, especially in women with polycystic ovarian syndrome. We have previously shown that MYO increases sperm motility in patients with asthenozoospermia by the increase of sperm mitochondrial membrane potential (MMP), a biofunctional sperm parameter closely associated to sperm motility. The aim of this study was to evaluate the effects of D-chiro-inositol (DCI), another biologically active isoform of inositols, on sperm MMP, as data on this matter has never been released so far. To accomplish this, semen samples from 15 patients with asthenozoospermia and 15 healthy normozoospermic men were incubated with increasing concentrations of DCI (0, 75, and 750 µg/mL) or phosphate buffer saline for 30 min. Incubation with DCI significantly improved sperm MMP at lower concentrations, and with shorter incubation length than those used in our similar MYO studies. In conclusion, these findings indicate that DCI positively impacts on sperm mitochondrial function in vitro. Studies aimed at assessing the role of DCI in the treatment of asthenozoospermia in-vivo are warranted.

Identifiants

pubmed: 32392776
pii: jcm9051373
doi: 10.3390/jcm9051373
pmc: PMC7290519
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Rev Endocr Metab Disord. 2018 Dec;19(4):349-354
pubmed: 30506520
Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):30-35
pubmed: 28724176
Hum Reprod. 2002 May;17(5):1257-65
pubmed: 11980749
Int J Endocrinol. 2016;2016:8720342
pubmed: 27882052
J Endocrinol Invest. 2014 Dec;37(12):1133-42
pubmed: 24923899
Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):129-34
pubmed: 21434479
Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):62-65
pubmed: 28724182
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1181-96
pubmed: 27351907
Gynecol Endocrinol. 2017 Jan;33(1):1-9
pubmed: 27898267
Urology. 2012 Jun;79(6):1290-5
pubmed: 22656408
Am J Physiol Cell Physiol. 2017 Aug 1;313(2):C146-C153
pubmed: 28515085
Mol Hum Reprod. 2011 Aug;17(8):457-65
pubmed: 21610215
J Clin Med. 2020 Jan 29;9(2):
pubmed: 32013061
Int J Endocrinol. 2016;2016:1674950
pubmed: 27752262
Cochrane Database Syst Rev. 2017 Nov 29;11:CD003053
pubmed: 29183107
Tissue Barriers. 2013 Apr 1;1(2):e23992
pubmed: 24665384
Mol Med. 2010 Nov-Dec;16(11-12):543-52
pubmed: 20811656

Auteurs

Rosita A Condorelli (RA)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Federica Barbagallo (F)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Aldo E Calogero (AE)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Rossella Cannarella (R)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Andrea Crafa (A)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Sandro La Vignera (S)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Classifications MeSH